Lenalidomide Capsule
Product Images NDC 47781-485

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 47781-485). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alvogen, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-itt-mm-1 (Figure Itt Mm 1)

A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time in months for three treatment groups: Rd Continuous, Rd18, and MPT. The chart includes confidence intervals (HR with 95% CI) and logrank p-value, along with a table of the number of subjects at risk and PFS event counts for each group.*

FDA Label Image

Figure-itt-mm-2 (Figure Itt Mm 2)

A survival probability curve chart comparing overall survival percentages over months across three groups: Rd Continuous, Rd18, and MPT. The chart includes hazard ratios with confidence intervals and a table indicating the number of subjects at risk at various time points. Rd Continuous shows the highest survival probability, followed by Rd18 and then MPT.*

FDA Label Image

Figure-mm-study-1 (Figure Mm Study 1)

A Kaplan-Meier survival curve chart showing time to progression (months) on the x-axis and proportion of subjects on the y-axis. Two groups are compared: Lenalidomide/Dex versus Placebo/Dex. The chart includes a hazard ratio (HR) with a 95% confidence interval and a log-rank p-value for statistical significance.*

FDA Label Image

Figure-mm-study-2 (Figure Mm Study 2)

A line graph showing time to progression (months) on the x-axis and proportion of subjects on the y-axis. It compares progression between two groups: Lenalidomide/Dex and Placebo/Dex, illustrating a higher proportion of subjects without progression over time in the Lenalidomide/Dex group. The graph includes a hazard ratio (HR) with 95% confidence interval and a p-value indicating statistical significance.*

FDA Label Image

Container Label 10mg Capsules (Label 10mg)

Label for Lenalidomide Capsules 10 mg by Alvogen, Inc. The label states each capsule contains 10 mg of Lenalidomide and includes warnings about potential human birth defects. It directs pharmacists to dispense the medication guide and notes the product is prescription only with 28 capsules per container. Storage instructions and manufacturing details are also provided.*

FDA Label Image

Container Label 15mg Capsules (Label 15mg)

Label for Lenalidomide Capsules, 15 mg, oral dosage form, containing 21 capsules. The label includes warnings about potential human birth defects and instructs pharmacists to dispense the medication guide. The labeler is Alvogen, Inc., with manufacturing by Lotus Pharmaceutical Co., Ltd. in Taiwan and product origin India. Storage instructions and color additive information are also present.*

FDA Label Image

Container Label 25mg Capsules (Label 25mg)

Label for Lenalidomide Capsules 25 mg by Alvogen, Inc. The label includes dosage strength, a pharmacist attention notice to dispense the Medication Guide, a warning about potential human birth defects, and storage instructions. Packaging contains 21 capsules. Manufacturer is Lotus Pharmaceutical Co., Ltd., Taiwan, distributed by Alvogen, Morristown, NJ, USA.*

FDA Label Image

Container Label 5mg Capsules (Label 5mg)

Label for Lenalidomide Capsules 5 mg by Alvogen, Inc. The label includes NDC 47781-484-28, dispensing instructions to pharmacists, storage conditions, manufacturing and distribution details, and container size of 28 capsules. The dosage form is oral capsules and the product is prescription only.*

FDA Label Image

Structure (Structure)

Chemical structure of lenalidomide, showing its molecular framework with a six-membered lactam ring connected to a benzene ring substituted with an amino group. The structure includes carbonyl groups and an amide linkage, consistent with lenalidomide's chemical identity.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.